TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have undergone first allo-HSCT from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative and myeloablative transplants are eligible.~* Clinically suspected Grades IIB to IVD acute GVHD as per modified MN-CIBMTR criteria, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic program.~* Subjects may, but are not required to, have previously received corticosteroids for acute GVHD:~* Evidence of myeloid engraftment. Use of growth factor supplementation is allowed.~Exclusion Criteria:~* Has received more than 1 hematopoietic stem cell transplantation.~* Has progressed on more than 2 prior treatment regimens for acute GVHD.~* Presence of an active uncontrolled infection.~* Subjects with relapsed primary disease, or subjects who have been treated for relapse after the allogeneic hematopoietic stem-cell transplantation (allo-HSCT) was performed.~* Inadequate recovery from toxicity and/or complications from the prior allo-HSCT.~* Any corticosteroid therapy (for indications other than GVHD) at doses \> 1 mg/kg per day methylprednisolone or equivalent within 7 days of randomization.~* Previously received JAK inhibitor therapy for any indication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Itacitinib (200 mg) (Type: EXPERIMENTAL): Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
- Itacitinib (300 mg) (Type: EXPERIMENTAL): Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytologic diagnosis of esophageal carcinoma~* ECOG performance status 0-1~* Age:70-85 years~* Joined the study voluntarily and signed informed consent form~* Patients must not have received any prior anticancer therapy~* Stage Ⅰ-ⅣB（AJCC 2009）~* Target lesions can be measured according to RECIST criteria~* No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN~Exclusion Criteria:~* Multiple carcinomas of the esophagus,~* Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula,~* Metastatic disease (M1b),~* A primary tumor that extended to within 2 cm of the gastroesophageal junction,~* Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor,~* history of a second malignancy other than nonmelanoma skin cancer

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- chemoradiotherapy (Type: EXPERIMENTAL): Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
- Radiotherapy 60 Gy (Type: ACTIVE_COMPARATOR): Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women who are 50 years or older~* ≥1 prescription fill for ABL or TPTD during the identification period~* ≥ 1 claim for medical or hospital visit and a pharmacy claim in the 12 months before the index date~Exclusion Criteria:~* Paget's disease~* Malignancy, except for nonmelanoma skin cancers, carcinoma in-situ of the cervix, ductal carcinoma in-situ of breast~* Indicators of high disease burden and high risk of death~* With prior index anabolic treatment~* Switch to a different anabolic treatment after index date

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients Treated with Abaloparatide (Type: None): Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
- Patients Treated with Teriparatide (Type: None): Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fast-track Surgery After Gynecological Oncology Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for gynecological oncology surgery(including radical hysterectomy add lymphadenectomy, hysterectomy add lymphadenectomy and cytoreductive)~2. Aged 18 years or older~3. Signed informed consent provided~Exclusion Criteria:~1. Patients with a documented infection at the time of operation~2. Aged 71 years or older~3. Patients with ileus at the time of operation~4. Patients with hypocoagulability~5. Patients with psychosis, Alcohol dependence or drug abuse history~6. Patients with primary nephrotic or hepatic disease~7. Patients with severe hypertension systolic pressure≥160mmHg, diastolic pressure\>90mmHg

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fast-track Surgery (Type: EXPERIMENTAL): Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
- Traditional surgery (Type: OTHER): pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer~  * Biopsy proven adenocarcinoma compatible with colorectal origin (primary tumor or metastasis)~ * If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the colon or rectum (scanning or endoscopy)~ * Non-resectable metastatic spread~* Previously exposed to or intolerance or contraindications to standard systemic therapy, defined as~  * oxaliplatin~ * irinotecan~ * 5-fluorouracil (or similar such as capecitabine, S1)~ * VEGF inhibitor bevacizumab~ * EGFR inhibitor panitumumab or cetuximab (if RAS/RAF wt)~* Progressive disease defined as progression according to RECIST 1.1~* ECOG performance status 0-2~* Age at least 18 years~* Adequate bone marrow, liver and renal function allowing systemic chemotherapy~  * Absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l.~ * Bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal value~ * Calculated or measured renal glomerular filtration rate at least 30 mL/min~* Anticonception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable~* Written and orally informed consent~Exclusion Criteria:~* Incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol~* Other active malignant disease requiring therapy~* Other systemic anti-cancer therapy (palliative radiotherapy is allowed).~* Pregnant (positive pregnancy test) or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: OTHER): 1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opaque Bottle Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mothers 18-40-years of age~* infants \<24-weeks of age~* predominantly bottle-feeding (\>50% of feedings)~* mother predominantly or solely responsible for infant feeding~* dyad has a pediatrician and plans to attend infant well-visits~* mother is willing to use stainless-steel bottles and to provide the study with her current bottles, which would be returned after study completion~* prior to the introduction of solid foods.~Exclusion Criteria:~* preterm birth (i.e., gestational age \<37 weeks)~* low birth weight (\<2500 g)~* maternal smoking during pregnancy~* current or past medical conditions that interfere with oral feeding~* history of slow growth or failure to thrive~* weight for length percentile \<5th~* diagnosed developmental delay (e.g., Down's syndrome)~* currently using opaque bottles

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Opaque Bottle Group (Type: EXPERIMENTAL): This group was given a set of opaque bottles to use during infant feedings for a full 12-week period.
- Clear Bottle Group (Type: ACTIVE_COMPARATOR): This group was given a set of clear bottles to use during infant feedings for a full 12-week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. English-speaking men and women (20-50 years old) of all ethnic origins~2. Outpatients with a current DSM-IV diagnosis of bipolar I with or without psychotic features or bipolar II disorder~3. Current cocaine or methamphetamine dependence~4. Currently experiencing hypomanic, manic, or mixed state episodes with a Young Mania Rating Scale23 (YMRS11) score of \> 9~5. Currently craving stimulants with a craving score of \> 20 on the 10-item, self-reported Stimulant Craving Questionnaire24 (SCQ10)~6. A high school diploma, GED, or Shipley IQ test score of \>85.~Exclusion criteria:~1. Inpatients or anyone with a high risk for suicide (i.e., active suicidal ideation with a proposed plan, history of any suicide attempt within the last 6 months)~2. DSM-IV diagnosis of substance-induced mood disorder~3. Pregnant or breast-feeding~4. History of special education, mental retardation, dementia~5. HIV/AIDS, reactive hepatitis, hepatic cirrhosis or any active liver disease, personal or familial history of diabetes, personal history of heart disease (i.e., congenital heart abnormalities, congestive heart failure, chronic atrial fibrillation, rheumatic heart disease, heart attack)~6. Central nervous system diseases (e.g., multiple sclerosis, severe head trauma, or seizures)~7. Contraindications or allergic reactions to study medications~8. Currently participating in any other research program~9. Urine positive for glucose or ketones~10. Currently receiving any antipsychotic medications or more than two psychotropic medications~11. Currently receiving benzodiazepines, sedatives or stimulants~12. Any other current substance dependence~13. Cataracts or glaucoma~14. EKG evidence of QT prolongation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Quetiapine versus Risperidone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sertraline to Prevent PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the Shriners Hospital or Massachusetts General Hospital for an acute burn, injury, or reconstructive surgery following a burn~* Between the ages of 6 - 20 years~* Recent experience of an acute burn, injury, or surgery meeting the Diagnostic and Statistical Manual(DSM-IV) A1 stressor criterion~* Child's response to the stressor meets Diagnostic and Statistical Manual(DSM-IV) A2 response criterion~* Proficiency in either English or Spanish~Exclusion Criteria:~* No memory of the injury~* Current use of an anti-depressant~* Known hypersensitivity to sertraline~* Diagnosis of Bipolar Disorder~* Diagnosis of PTSD~* Mental Retardation~* Traumatic Brain Injury~* New onset or marked worsening of a seizure disorder

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
- Sertraline (Type: EXPERIMENTAL): Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy non-pregnant adults~* Available in the study area for 1 month~Exclusion Criteria:~* Diarrhea for the past week~* Antibiotic use in the past week~* Intake of anti-diarrheal medicines in the past week~* One or more episodes of diarrhea or abdominal pain lasting for 2 weeks during the past 6 months~* Abdominal pain, nausea, vomiting, loss of appetite or generalized ill feeling for the past 24 hours~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a morphologically proven diagnosis AML and both the two following criteria: Age \> 50 years and £ 70 years. Not previously treated for their disease.~* ECOG performance status 0 to 3~* Negative serology HIV, HBV and HBC (except post vaccination)~* Serum creatinin inf 2.5N; AST and ALT inf 2.5N; total bilirubin inf 2N~* Cardiac function determined by radionucleide or echography within normal limits.~* Negative serum pregnancy test within one week before treatment for women of child bearing potential.~* Signed informed consent.~Exclusion Criteria:~* M3-AML~* AML following previously know myeloproliferative syndrome.~* Known central nervous system involvement.~* Uncontrolled infection~* Other active malignancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A Daunorubicin and Cytarabine (Type: ACTIVE_COMPARATOR): Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
- Arm B Daunorubicin and Cytarabine and Mylotarg (Type: EXPERIMENTAL): Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants legally competent to sign and give informed consented and if appropriate assent as required by local laws~* Males and females ages 2 years and older (inclusive)~* Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator~* Females of childbearing potential (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.~* In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.~* Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.~Exclusion Criteria:~* Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.~  * Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~ * Previous treatment with ARQ-151 or its active ingredient~ * Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.~ * Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product~ * Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ-151 cream 0.3% (Type: ACTIVE_COMPARATOR): Active comparator
- ARQ-151 cream vehicle (Type: PLACEBO_COMPARATOR): Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who completed Study SP665, SP742, or SP768 and, in the investigators opinion, might benefit from long-term administration of SPM 927. Exception: subjects who prematurely discontinued Study SP742 or SP768 due to lack of efficacy or due to intolerability to trial medication may be eligible to participate in Study SP745, after consultation with the medical monitor.~Exclusion Criteria:~* Subject has clinically relevant electrocardiogram (ECG) abnormalities, or QT-corrected (QTc) interval \>=500 milliseconds (ms), and/or a QTc interval increase of \>=60ms from the mean pre-dose QTc value at Visit 2 of Studies SP665, SP742 or SP768.~* Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>=3 times the upper limit of the normal range (ULN) with total bilirubin \>=2 times ULN or transaminases (AST and/or ALT) \>=5 times ULN.~* Subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial.

- Gender: ALL
- Minimum Age: 32 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete